Pharmacokinetic and drug absorption profiles of the anti-hyperglycaemic agent gliclazide in oral tissue-targeted microcapsules in rats

This article should be cited as follows: Jovic J, Milijasevic B, Vukmirovic S, Vasovic V, Mikov M, Mooranian A, Al-Salami H, Golocorbin-Kon S. Pharmacokinetic and drug absorption profiles of the antihyperglycaemic agent gliclazide in oral tissue-targeted microcapsules in rats. Scr Med 2020;51(1):15-20. Received: 2 March 2020 Revision received: 16 March 2020 Accepted: 17 March 2020 ARTICLE INFO (1)

[1]  N. Pavlović,et al.  Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics , 2018, European Journal of Drug Metabolism and Pharmacokinetics.

[2]  S. Vukmirović,et al.  High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect , 2017, European Journal of Drug Metabolism and Pharmacokinetics.

[3]  F. Arfuso,et al.  A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes , 2016, Drug delivery.

[4]  H. Al‐Salami,et al.  An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations , 2015, Pharmaceutical development and technology.

[5]  Hesham S. Al-Sallami,et al.  Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment , 2015, Journal of microencapsulation.

[6]  S. Genuth.  Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On! , 2014, Diabetes Care.

[7]  Hesham S. Al-Sallami,et al.  Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study , 2014, Drug design, development and therapy.

[8]  H. Al‐Salami,et al.  Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics , 2014, Journal of Pharmaceutical Innovation.

[9]  I. Tucker,et al.  Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats , 2012, European Journal of Drug Metabolism and Pharmacokinetics.

[10]  A. Tiwari,et al.  Pharmacological and Pharmaceutical Profile of Gliclazide: A Review. , 2011 .

[11]  M. Namba,et al.  Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. , 2010, Metabolism: clinical and experimental.

[12]  A. Rašković,et al.  The influence of 3α,7α-dihydroxy-12-keto-5β-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes , 2008, European Journal of Drug Metabolism and Pharmacokinetics.

[13]  R. Al-Kassas,et al.  Controlling of systemic absorption of gliclazide through incorporation into alginate beads. , 2007, International journal of pharmaceutics.

[14]  J. Kvetina,et al.  Gliclazide: pharmacokinetic–pharmacodynamic relationships in rats , 2007, Biopharmaceutics & drug disposition.

[15]  A. Hoffman,et al.  Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[16]  I. Wilding,et al.  Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. , 2000, British journal of clinical pharmacology.

[17]  P. Jennings.  Vascular benefits of gliclazide beyond glycemic control. , 2000, Metabolism: clinical and experimental.

[18]  J. Beilby,et al.  Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. , 2000, British journal of clinical pharmacology.

[19]  A. Desfaits,et al.  Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL. , 1997, Metabolism: clinical and experimental.

[20]  M. Resztak,et al.  Pharmacokinetics and Pharmacodynamics of Gliclazide from Immediate and Modified Release Formulation Tablets in Rats , 2014, Iranian journal of pharmaceutical research : IJPR.

[21]  C. Perry,et al.  Gliclazide Modified Release , 2012, Drugs.

[22]  A. Rašković,et al.  The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. , 2008, European journal of drug metabolism and pharmacokinetics.